DWTX — Dogwood Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818844 ·
Last close
$1.36
Market Cap
$46.23M
52W High
$9.50
52W Low
$1.28
ADV30
76,150
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,872,628 | -11,529,609 | 80,495,480 | 9,610,033 | 12,129,372 |
| Mar 2026 | 0 | — | -5,076,366 | -4,986,614 | 95,207,871 | 13,227,839 | 14,584,519 |
| Dec 2025 | 0 | — | -3,806,279 | -3,780,449 | 90,171,237 | 6,524,744 | 15,274,370 |
| Sep 2025 | 0 | — | -15,809,125 | -15,744,616 | 91,992,613 | 10,126,710 | 14,607,504 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,523,284
Investing CF
—
Financing CF
$11,203,753
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.60
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-113,062,930
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-28,614,885
Pretax Income TTM
$-28,287,285
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -27,968,445 | -34,257,370 | 90,171,237 | 15,274,370 | 74,896,867 | -15,618,651 |
| Dec 2024 | 0 | -12,227,248 | -12,349,724 | 94,308,246 | 30,027,223 | 64,281,023 | -8,790,805 |
| Dec 2023 | 0 | -5,446,919 | -5,296,015 | 4,165,442 | 358,548 | 3,806,894 | -4,870,489 |
| Dec 2022 | 0 | -12,315,309 | -12,247,834 | 8,369,756 | 1,043,262 | 7,326,494 | -11,467,797 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | $46.66M | $0.96 | — |
| PDSB | PDS Biotechnology Corp | $44.61M | $0.80 | — |
| GRCE | Grace Therapeutics, Inc. | $44.60M | $2.12 | — |
| ELTX | Elicio Therapeutics, Inc. | $48.36M | $1.84 | — |
| SCYX | SCYNEXIS INC | $43.68M | $4.39 | — |
News headlines (Yahoo Finance, 1h cache)
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
2026-09-14 12:45 · Yahoo
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
2026-09-01 22:01 · Yahoo
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
2026-08-17 12:30 · Yahoo
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
2026-08-13 12:30 · Yahoo
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
2026-07-20 12:30 · Yahoo
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
2026-06-30 12:45 · Yahoo
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
2026-05-18 12:45 · Yahoo
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
2026-05-07 12:30 · Yahoo
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
2026-04-15 13:00 · Yahoo
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
2026-04-23 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.